Company Interview / Compumedics dreams bigger as sleep diagnostics scale

Key points:

Record FY26 revenue of $60.3 million and improved profitability and cash flowSomfit and Nexus 360 sleep diagnostics cited as core growth drivers in the US and clinical trialsMEG business expanding, with focus on China and a return to the North American market

David Lawson, the CFO of Compumedics (ASX:CMP), outlines what he views as a strong full-year 2026 performance, highlighting record revenue of $60.3 million, a return to profitability and significantly improved operating cash flow. Lawson points to software-led sleep diagnostics and the magnetoencephalography (MEG) business as the main engines of growth, with Nexus 360 sleep software growing from virtually nothing to just over $10 million in three years, and MEG delivering $9.7 million after no contribution last year.

Lawson states that Compumedics remains focused on double-digit revenue growth in FY27, with earnings expected to grow faster than revenue through cost efficiencies and a solid order book. A key driver, in his view, is the Somfit sleep device, which he says is already commercial in a reusable form in the United States, with a disposable version only months from broader market launch. He characterises Somfit as a shift from low-volume capital equipment to high-volume devices.

Looking ahead, Lawson sees substantial opportunity in US home sleep testing, given more than four million studies annually, and in pharmaceutical clinical trials, where sleep impact must be monitored. He also anticipates renewed MEG system sales in North America, emphasising Compumedics’ dual-helmet technology for both adult and paediatric patients.